Equities research analysts expect Coherus Biosciences Inc (NASDAQ:CHRS) to announce ($0.82) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Coherus Biosciences’ earnings, with estimates ranging from ($0.90) to ($0.75). Coherus Biosciences reported earnings of ($0.84) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 2.4%. The company is expected to report its next quarterly earnings report on Thursday, March 14th.

On average, analysts expect that Coherus Biosciences will report full year earnings of ($3.12) per share for the current fiscal year, with EPS estimates ranging from ($3.20) to ($3.04). For the next year, analysts forecast that the company will post earnings of ($1.42) per share, with EPS estimates ranging from ($2.16) to $0.02. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Coherus Biosciences.

Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.08).

A number of equities analysts have commented on the stock. ValuEngine raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. BidaskClub raised shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, January 31st. Zacks Investment Research raised shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, January 9th. Finally, HC Wainwright set a $28.00 target price on shares of Coherus Biosciences and gave the stock a “buy” rating in a research note on Monday, November 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Coherus Biosciences currently has a consensus rating of “Buy” and a consensus price target of $27.20.

Institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new stake in shares of Coherus Biosciences in the 2nd quarter valued at approximately $118,000. Roman Butler Fullerton & Co. purchased a new stake in shares of Coherus Biosciences in the 4th quarter valued at approximately $122,000. Renaissance Technologies LLC purchased a new stake in shares of Coherus Biosciences in the 3rd quarter valued at approximately $282,000. State Board of Administration of Florida Retirement System increased its stake in Coherus Biosciences by 16.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 22,095 shares of the biotechnology company’s stock worth $200,000 after buying an additional 3,122 shares during the period. Finally, BlueMountain Capital Management LLC increased its stake in Coherus Biosciences by 110.9% during the 3rd quarter. BlueMountain Capital Management LLC now owns 32,257 shares of the biotechnology company’s stock worth $532,000 after buying an additional 16,960 shares during the period. 93.58% of the stock is currently owned by institutional investors and hedge funds.

CHRS traded down $0.33 on Monday, reaching $13.75. 389,833 shares of the company’s stock were exchanged, compared to its average volume of 792,635. The firm has a market capitalization of $957.79 million, a PE ratio of -3.07 and a beta of 3.66. Coherus Biosciences has a twelve month low of $8.32 and a twelve month high of $20.66. The company has a current ratio of 5.31, a quick ratio of 5.31 and a debt-to-equity ratio of 8.29.

About Coherus Biosciences

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Recommended Story: What is the S&P 500 Index?

Get a free copy of the Zacks research report on Coherus Biosciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.